Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

2009 • 78,446 citations

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

2009 • 20,118 citations

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

2010 • 9,719 citations

Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer

1999 • 3,538 citations

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

2013 • 2,055 citations

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

2010 • 2,043 citations

Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients

1996 • 1,658 citations

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

2014 • 1,587 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases

2002 • 1,450 citations

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

2009 • 1,286 citations

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

2011 • 923 citations

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 • 832 citations

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

2015 • 715 citations

Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis

2009 • 708 citations

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

2011 • 708 citations

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 • 602 citations

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 • 549 citations

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

2009 • 539 citations

Guidelines for resection of colorectal cancer liver metastases

2006 • 405 citations

Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

2012 • 347 citations

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

2013 • 346 citations

Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas

2012 • 264 citations

Raf kinase as a target for anticancer therapeutics

2005 • 245 citations

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

2015 • 226 citations

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

2011 • 205 citations

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

2010 • 203 citations

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

2011 • 199 citations

Signaling pathways in Ras-mediated tumorigenicity and metastasis

1998 • 194 citations

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

2013 • 182 citations

KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

2009 • 162 citations

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

2015 • 157 citations

KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases

2014 • 138 citations

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

2012 • 134 citations

The Clinical Risk Score

2004 • 111 citations

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

2010 • 106 citations

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

2012 • 81 citations

K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis

1992 • 77 citations

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab

2012 • 68 citations

Predictors of cure after hepatic resection of colorectal liver metastases: An analysis of actual 5‐ and 10‐year survivors

2011 • 66 citations

Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity

1994 • 64 citations

Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases.

2002 • 59 citations

Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: Comparison of our scoring system to the positive number of risk factors

2006 • 50 citations

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2009 • 45 citations

EGFR genomic alterations in cancer prognostic and predictive values

2011 • 42 citations

Patterns of Referral and Resection Among Patients with Liver-Only Metastatic Colorectal Cancer (MCRC)

2010 • 41 citations

K-ras Status Does Not Predict Successful Hepatic Resection of Colorectal Cancer Metastasis

1995 • 38 citations

The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

2009 • 34 citations

The role of targeted therapy for gastrointestinal tumors

2014 • 32 citations

Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

2009 • 30 citations

Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases

1998 • 29 citations

Proposal of a new and simple staging system of colorectal liver metastasis

2006 • 29 citations

The BRAF mutation is associated with the prognosis in colorectal cancer

2014 • 22 citations

Monoclonal antibodies in gastrointestinal cancers

2013 • 22 citations

Prognostic significance of proliferative activity, DNA‐ploidy, p53 and Ki‐ras point mutations in colorectal liver metastases

1998 • 22 citations

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario

2014 • 9 citations

BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).

2014 • 1 citations